

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 20609/191 (UTRC 00035)	SERIAL NO. To Be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Robert H. Lustig	
(use several sheets if necessary)		FILING DATE Herewith	GROUP ART UNIT To Be Assigned
(PTO-1449)		J1046 U.S. PTO 10/06/03 11/08/01	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>HL</i>	1	4,853,371	08/01/89	Coy et al.			
<i>HL</i>	2	6,123,916	09/26/00	Krenning et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION IF APPROPRIATE
<i>HL</i>	3	WO 98/51331	11/19/98	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

<i>HL</i>	4	Lotter et al., "Somatostatin Decreases Food Intake of Rats and Baboons," <i>Journal of Comparative and Physiological Psychology</i> 95:278-287 (1981)
<i>HL</i>	5	Levine et al., "Peripherally Administered Somatostatin Reduces Feeding by a Vagal Mediated Mechanism," <i>Pharmacology Biochemistry & Behavior</i> 16:897-902 (1982)
<i>HL</i>	6	"Correlations Between Autonomic Function, β -Cell Activity, Insulin Sensitivity, and Glucose Tolerance in Obese Subjects," The Endocrine Society's 82 nd Annual Meeting, Abstract, Document 1 (June 2000)
<i>HL</i>	7	Lustig et al., "Hypothalamic Obesity Caused by Cranial Insult in Children: Altered Glucose and Insulin Dynamics and Reversal by a Somatostatin Agonist," <i>The Journal of Pediatrics</i> 135:162-168 (August 1999)
<i>HL</i>	8	Lustig, "Childhood Obesity," Serono Symposia USA, Inc. and The Lawson Wilkins Pediatric Endocrine Society's Serono Symposia USA, San Francisco, CA. Pp. 133-139 (April 1999)
<i>HL</i>	9	Velasquez et al., "Monthly Injections of Long-Acting Octreotide Promote Insulin Suppression and Weight Loss in Adults with Severe Obesity," The Endocrine Society's Obesity II Poster Session, Abstract No. 2063, Board 498 (June 2000?)
<i>HL</i>	10	Sigal et al., "Acute Postchallenge Hyperinsulinemia Predicts Weight Gain: A Prospective Study," <i>Diabetes</i> 46:1025-1029 (1997)
<i>HL</i>	11	Le Stunff et al., "Early Changes in Postprandial Insulin Secretion, Not in Insulin Sensitivity, Characterize Juvenile Obesity," <i>Diabetes</i> 43:696-701 (1994)
<i>HL</i>	12	Campfield et al., "Insulin Normalization as an Approach to the Pharmacological Treatment of Obesity," <i>Obesity Research</i> 3(Suppl. 4):591S-603S (1995)

EXAMINER	<i>Robert H. Lustig</i>	DATE CONSIDERED	9/30/03
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	20609/191 (UTRC 00035)	To Be Assigned
	APPLICANT Robert H. Lustig	
	FILING DATE	GROUP ART UNIT
	Herewith	To Be Assigned

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION IF APPROPRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)